Andrew Polovin Sells 22,148 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 22,148 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $1,098,762.28. Following the completion of the transaction, the executive vice president directly owned 146,067 shares in the company, valued at approximately $7,246,383.87. The trade was a 13.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, August 19th, Andrew Polovin sold 7,927 shares of Tempus AI stock. The shares were sold at an average price of $56.00, for a total value of $443,912.00.

Tempus AI Stock Up 9.1%

Shares of Tempus AI stock opened at $72.69 on Friday. The firm has a market cap of $13.12 billion, a price-to-earnings ratio of -50.48 and a beta of 3.58. The stock has a 50-day simple moving average of $52.93 and a 200-day simple moving average of $51.36. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm’s revenue was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.22) earnings per share. On average, equities research analysts expect that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Tempus AI

A number of institutional investors have recently made changes to their positions in the business. GC Wealth Management RIA LLC bought a new stake in Tempus AI during the fourth quarter worth about $399,267,000. Voloridge Investment Management LLC boosted its holdings in shares of Tempus AI by 183.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after buying an additional 1,039,176 shares during the period. AQR Capital Management LLC acquired a new position in Tempus AI in the 2nd quarter valued at about $54,020,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after acquiring an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. lifted its position in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after acquiring an additional 821,490 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TEM. BTIG Research boosted their target price on Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday. Guggenheim lifted their target price on Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Piper Sandler lowered their price target on shares of Tempus AI from $58.00 to $56.00 and set a “neutral” rating on the stock in a report on Tuesday, August 4th. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a research note on Friday, July 31st. Finally, Weiss Ratings raised Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Nine investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $65.69.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.